Novelion Therapeutics
Vancouver · Founded 1981
About Novelion Therapeutics
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
Company Facts
- Founded: 1981
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $72.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (Aug 2021)
- Ticker: nasdaq:NVLN
- Website: novelion.com
- Phone: 604.707.7000
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Canonical: https://fsome.com/organization/novelion-therapeutics-173274 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.